🇺🇸 FDA
Patent

US 11760803

Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments

granted A61KA61K2039/507A61P

Quick answer

US patent 11760803 (Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments) held by Takeda Pharmaceutical Company Limited expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/507, A61P, A61P35/00, A61P37/06